1887
3 - The International and Scientific Conference of Alnahrain College of Medicine and Colleges of Medicine in Iraq confronting COVID-19 Pandemic (ISMC-2022)
  • ISSN: 1999-7086
  • EISSN: 1999-7094

Abstract

Innate immunity plays an important role in deciding the severity of coronavirus disease 2019 (COVID-19) and disease outcomes. Defensins are antimicrobial peptides that are produced by epithelial cells in mucosal locations and play a key role in innate immunity. Understanding COVID-19 mucosal agents and their role in disease severity is critical for developing therapeutic options and identification of prognostic markers for COVID-19. In this study, we aimed to determine the role of β-defensin-1 in patients with COVID-19 and compare it with that of the control group, as well as to look into the link between β-defensin-1 and oral hygiene and disease severity. This case-control study included 50 patients with COVID-19 and 35 controls of similar ages and sexes. From November 2020 to January 2021, the patients were admitted to Baghdad Teaching Hospital/Medical City. The simplified oral hygiene index was used to determine oral hygiene status. Blood samples were obtained from all subjects (patients and controls), and the serum levels of β-defensin-1 were measured using enzyme-linked immunosorbent assay (ELISA). Findings showed a non-significant reduction (P>0.05) in the β-defensin-1 level among patients compared with that of the controls. In addition, patients with severe disease had a significantly lower level of β-defensin-1 than those with mild disease. There were no significant variations in the levels of β-defensin-1 between patients with good oral hygiene and those with poor oral hygiene (>0.05). The reduction in β-defensin-1 levels indicates an abnormal immune response in these patients and may require a new treatment option for this condition in the future. Furthermore, in patients with severe disease, a considerable drop in β-defensin-1 might be used as an indicator of illness severity.

Loading

Article metrics loading...

/content/journals/10.5339/jemtac.2022.ismc.2
2022-05-30
2022-07-01
Loading full text...

Full text loading...

/deliver/fulltext/jemtac/2022/3/jemtac.2022.ismc.2.html?itemId=/content/journals/10.5339/jemtac.2022.ismc.2&mimeType=html&fmt=ahah

References

  1. Cheng VCC, Lau SKP, Woo PCY, Yuen KY. Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection. Clin Microbiol Rev. 2007; 20:(4):660–94.
    [Google Scholar]
  2. Hui DS, et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health – the latest 2019 novel coronavirus outbreak in Wuhan, China. Intl J Infect Dis. 2020;:91:264–66.
    [Google Scholar]
  3. Wu JT, Leung K, Leung, GM. Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study. Lancet. 2020;:395:689–97.
    [Google Scholar]
  4. Chan JFW, Kok KH, Zhu Z, et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect. 2020; 9:(1):221–36.
    [Google Scholar]
  5. Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS. J Virol. 2020; 94:(7):e00127–20.
    [Google Scholar]
  6. Feng Y, Ling Y, Bai T, et al. COVID-19 with different severities: a multi-centre study of clinical features. Am J Respir Crit Care Med. 2020;:201:1380–88.
    [Google Scholar]
  7. Yang D, Biragyn A, Hoover DM, Lubkowski J, Oppenheimmultiple JJ. Roles of antimicrobial defensins, cathelicidins, and eosinophil-derived neurotoxin in host defense. Annu Rev Immunol. 2004;:22:181–215.
    [Google Scholar]
  8. Selsted M, Ouellettemammalian AJ. defensins in the antimicrobial immune response. Nat Immunol. 2005;:6:551–57.
    [Google Scholar]
  9. Al-Ali GM, Jafar ZJ, AL-Ghurabi BH. The relation of salivary cathelicidin and beta-defensin with dental caries of schoolchildren. J Res Med Dent Sci. 2021; 9:(4):30–5.
    [Google Scholar]
  10. Pazgier M, Hoover DM, Yang D, Lu W, Lubkowski J. Human beta-defensins. Cell Mol Life Sci. 2006;:63:1294–313.
    [Google Scholar]
  11. Wang C, Wang S, Li D, Wei DQ, Zhao J, Wang J. Human intestinal defensin 5 inhibits SARS-CoV-2 invasion by cloaking ACE2. Gastroenterology. 2020;:159:1145–7.
    [Google Scholar]
  12. Idris M, Banu S, Siva AB, Nagaraj R. Downregulation of defensin genes in SARS-CoV-2 infection. Med Rxiv. doi:10.1101/2020/09.21.20195537.
    [Google Scholar]
  13. World Health Organization. 2020. Coronavirus disease 2019 (COVID-19).
    [Google Scholar]
  14. Greene JC, Vermillion JR. The simplified oral hygiene index. J Am Dent Assoc. 1964;:68:7–13.
    [Google Scholar]
  15. Jaillon S, Berthenet K, Garlanda C. Sexual dimorphism in innate immunity. Clin Rev Allergy Immunol. 2019;:56:308–21.
    [Google Scholar]
  16. Zeina SA, Al-Ghurabi BH. Serum Level of cathelicidin in Covid-19 patients in relation with oral health. J Res Med Dent Sci. 2021; 9:(7):85–9.
    [Google Scholar]
  17. Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ, et al. Clinical characteristics of 140 patients infected by SARS-CoV-2 in Wuhan, China. Allergy. 2020; 75:(7):1730–41.
    [Google Scholar]
  18. Argenziano MG, Bruce SL, Slater CL, Tiao JR, Baldwin MR, Barr RG, et al. Characterization and clinical course of 1000 patients with coronavirus disease 2019 in New York: retrospective case series. BMJ. 2020;:29:369. PMID: 32471884.
    [Google Scholar]
  19. Brann DH, Tsukahara T, Weinreb C, Logan DW, Datta SR. Non-neural expression of SARS-CoV 2 entry genes in the olfactory epithelium suggests mechanisms underlying anosmia in COVID-19 patients. Sci Adv. 2020; 6:(31).
    [Google Scholar]
  20. Sia SF, Yan LM, Chin AWH, et al. Pathogenesis and transmission of SARS-CoV-2 in golden hamsters. Nature. 2020;:583:834–8.
    [Google Scholar]
  21. Al-Ghurabi BH, Al-Saadi LG, Al-Hindaw SH. Pro- and anti-inflammatory cytokines in coronavirus disease 2019. Medico-legal Update. 2020; 20:(4):144–6.
    [Google Scholar]
  22. Weiss P, Murdoch DR. Clinical course and mortality risk of severe COVID-19. Lancet. 2020; 395:(10229):1014–5.
    [Google Scholar]
  23. Woo K. A pilot study to examine the relationships of dyspnoea, physical activity, and fatigue in patients with chronic obstructive pulmonary disease. J Clin Nurs. 2000; 9:(4):1–8.
    [Google Scholar]
  24. Khan AA, Khan Z. COVID-2019 associated overexpressed Prevotella proteins mediated host-pathogen interactions and their role in coronavirus outbreak. Bioinformatics. 2020;:36:4065–9.
    [Google Scholar]
  25. Kamel A, Basuoni A, Salem Z, et al. The impact of oral health status on COVID-19 severity, recovery period and C-reactive protein values. Br Dent J. 2021;1–7.
    [Google Scholar]
  26. Cao X. COVID-19: immunopathology and its implications for therapy. Nature Rev Immunol. 2020;:20:269–70.
    [Google Scholar]
  27. Shin JE, Choi Y. Treponema denticola suppresses expression of human production and TLR2 activation. Mol Cells. 2010; 29:(4):407–12.
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.5339/jemtac.2022.ismc.2
Loading
/content/journals/10.5339/jemtac.2022.ismc.2
Loading

Data & Media loading...

  • Article Type: Research Article
Keyword(s): antimicrobial peptideCOVID-19defensin and SARS-CoV-2
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error